Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Wenninger
In der Rubrik Zeitschriften haben wir 1 Beitrag für Sie gefunden
-
MerkenBig Pharma at the Crossroads
Rubrik: Pharma-Markt
(Treffer aus pharmind, Nr. 01, Seite 44 (2015))
Müller M |
Big Pharma at the Crossroads / Recent strategic moves of globally acting pharmaceutical companies · Müller M, Wenninger1 The views expressed in this article are the views and opinions of the authors b">Wenninger 1 The views expressed in this article are the views and opinions of the authors b 1 The views expressed in this article are the views and opinions of the authors b · Cepton GmbH, München, Germany
On average, pharma and biotech stocks have shown good performance in 2013, however, most of Big Pharma´s stock price development in 2013 lagged behind the S&P 500 and Dax average. The impact of payors and regulatory bodies continues to grow, influencing not only market access activities, but R&D decisions and business models. Diversification has seen first limits and big players like Abbott, Pfizer and BMS have started to re-focus. Biosimilars and over-the-counter (OTC) drugs have re-entered the spotlight. Regional focus is partly moving on from China to “second-tier” emerging markets like South-East Asia, Iran, Pakistan and Africa. A decrease in ...
